Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use
- PMID: 33769855
- PMCID: PMC10391241
- DOI: 10.18553/jmcp.2021.27.4.536
Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use
Abstract
DISCLOSURES: No funding was received for the writing of this article. Parcher is employed by Xcenda and has nothing to disclose. Coder is employed by Digital Therapeutics Alliance, which is a member of the USP Convention. Coder reports fees from PsychU/Otsuka.
Conflict of interest statement
No funding was received for the writing of this article. Parcher is employed by Xcenda and has nothing to disclose. Coder is employed by Digital Therapeutics Alliance, which is a member of the USP Convention. Coder reports fees from PsychU/Otsuka.
References
-
- U.S. Food and Drug Administration. Guidances with digital health content. Updated October 6, 2020. Accessed March 6, 2021. https://www.fda.gov/medical-devices/digital-health/guidances-digital-hea...
-
- Digital Therapeutics Alliance. About DTA. January 1, 2020. Accessed March 6, 2021. https://dtxalliance.org/about-dta/
-
- Digital Therapeutics Alliance. Ensuring appropriate quality, access, and utilization of digital therapeutics. Fact sheet. April 2020. Accessed March 6, 2021. https://dtxalliance.org/wp-content/uploads/2020/04/DTx_Quality_Access_Ut...
-
- Digital Therapeutics Alliance. Digital therapeutics definition and core principles. Fact sheet. November 2019. Accessed March 6, 2021. https://dtxalliance.org/wp-content/uploads/2019/11/DTA_DTx-Definition-an...
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
